There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harmony Biosciences Holdings (HRMY – Research Report), Moderna (MRNA – Research Report) and Ionis Pharmaceuticals (IONS – Research Report) with bullish sentiments.
Harmony Biosciences Holdings (HRMY)
Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $50.00. The company’s shares closed last Monday at $29.25.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harmony Biosciences Holdings with a $42.00 average price target.
See today’s best-performing stocks on TipRanks >>
Moderna (MRNA)
Oppenheimer analyst Hartaj Singh maintained a Buy rating on Moderna today and set a price target of $142.00. The company’s shares closed last Monday at $111.62.
According to TipRanks.com, Singh is a 5-star analyst with an average return of
Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $122.87.
Ionis Pharmaceuticals (IONS)
Oppenheimer analyst Jay Olson maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $75.00. The company’s shares closed last Monday at $41.99.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $58.69 average price target, representing a 40.6% upside. In a report issued on April 26, Piper Sandler also assigned a Buy rating to the stock with a $63.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HRMY:
- Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
- Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
- Harmony Biosciences signs exclusive licensing agreement for sleeping disorders
- Harmony Biosciences begins Phase 3 registrational study of pitolisant in PWS
- Harmony Biosciences management to meet with Oppenheimer
